Skip to main content

Military Health System

Test of Sitewide Banner

This is a test of the sitewide banner capability. In the case of an emergency, site visitors would be able to visit the news page for addition information.

Development of WRAIR’s Pan-Coronavirus Vaccine Shows Promise

Image of A vial of spike ferritin nanoparticle WRAIR's COVID-19 vaccine. A vial of spike ferritin nanoparticle (SpFN), WRAIR’s COVID-19 vaccine. Built on a ferritin platform, the vaccine offers a flexible approach to targeting multiple variants of the virus that causes COVID-19 and potentially other coronaviruses as well (Photo by: Mike Walters, Walter Reed Army Institute of Research).

A series of recently published preclinical study results show that the Spike Ferritin Nanoparticle (SpFN) COVID-19 vaccine developed by researchers at the Walter Reed Army Institute of Research in Silver Spring, Maryland not only elicits a potent immune response but may also provide broad protection against SARS-CoV-2 variants of concern as well as other coronaviruses.

Scientists in WRAIR's Emerging Infectious Diseases Branch (EIDB) developed the SpFN nanoparticle vaccine, based on a ferritin platform, as part of a forward-thinking "pan-SARS" strategy that aims to address the current pandemic and acts as a first line of defense against variants of concern and similar viruses that could emerge in the future.

"The accelerating emergence of human coronaviruses throughout the past two decades and the rise of SARS-CoV-2 variants, including most recently Omicron, underscore the continued need for next-generation preemptive vaccines that confer broad protection against coronavirus diseases," said Dr. Kayvon Modjarrad, director of the Emerging Infectious Diseases Branch at WRAIR, co-inventor of the vaccine and the Army lead for SpFN. "Our strategy has been to develop a 'pan-coronavirus' vaccine technology that could potentially offer safe, effective and durable protection against multiple coronavirus strains and species."

Pre-clinical studies published today in Science Translational Medicine indicate that the SpFN vaccine protects non-human primates from disease caused by the original strain of SARS-CoV-2 and induces highly-potent and broadly-neutralizing antibody responses against major SARS-CoV-2 variants of concern including the SARS-CoV-1 virus that emerged in 2002.

SpFN entered Phase 1 human trials in April 2021. Early analyses, expected to conclude this month, will provide insights into whether SpFN's potency and breadth, as demonstrated in preclinical trials, will carry over into humans. The data will also allow researchers to compare SpFN's immune profile to that of other COVID-19 vaccines already authorized for emergency use.

"This vaccine stands out in the COVID-19 vaccine landscape," Modjarrad said. "The repetitive and ordered display of the coronavirus spike protein on a multi-faced nanoparticle may stimulate immunity in such a way as to translate into significantly broader protection."

WRAIR developed a secondary candidate vaccine, a SARS-CoV-2 Spike Receptor-Binding Domain Ferritin Nanoparticle (RFN) vaccine, which targets a smaller part of the coronavirus Spike protein than the SpFN vaccine. Results from a study, published recently in the Proceedings of the National Academy of Sciences, show that this vaccine potentially offers similar protection against an array of SARS-CoV-2 variants and SARS-CoV-1.

"The RFN vaccine candidate is more compact and has some natural advantages as we try to increase the immune response against multiple coronaviruses using a single vaccine platform, so it is still under consideration as part of our pan-coronavirus vaccine development pipeline," said Dr. Gordon Joyce, WRAIR structural biologist and vaccine co-inventor.

"The threat from COVID-19 continues as it evolves, and eventually there will be other emerging disease threats," said Dr. Nelson Michael, director of the Center for Infectious Diseases Research at WRAIR. "Our investment in developing a next generation vaccine is an important step towards getting ahead of COVID-19 and future disease threats."

You also may be interested in...

How COVID-19 Public Health Emergency’s End Affects TRICARE

Article Around MHS
5/16/2023
Immunization Clinic photo

The Public Health Emergency (PHE) for COVID-19 expired at the end of May 11. You might be wondering what this means about the state of COVID-19 or if there are changes to your TRICARE coverage.

COVID-19 Registry Provides Pandemic Response Insights, Optimizes Patient Care

Article
3/28/2023
COVID-19 Registry Provides Pandemic Response Insights, Optimizes Patient Care

Prior to the pandemic, the DOD began deploying MHS GENESIS, the new federal electronic health record, to improve health care outcomes for our service members, veterans, and their families. Critical enterprise needs quickly came to light to combat the impacts of the COVID-19 disease.

Navy’s Global Engagement Helps Identify and Mitigate Disease

Article
3/22/2023
Navy’s Global Engagement Helps Identify and Mitigate Disease

In support of the Military Health System, the Naval Medical Research Unit-2 is just one global entity that works with local partners to identify and combat global health threats.

Genome Sequencing Assists Research at Naval Health Research Center

Article
1/24/2023
Lab technicians doing genome research

Learn how unique samples from naval vessels, US-Mexico border populations, and DOD beneficiaries aided in the Naval Health Research Center’s sequencing efforts.

U.S. Military HIV Research Lends Lessons Learned to COVID-19

Article
1/19/2023
Gloved hands working in laboratory

The U.S. military has engaged in HIV research for three decades, contributing critical lessons learned, knowledge, and expertise during the COVID-19 research and vaccine development effort.

Naval Medical Research Center Uses Genome Sequencing for Variants

Article
1/12/2023
Military personnel pose for a group photo

NMRC’s efforts provided important support for sequencing and viral isolation to the Department of Defense and Military Health System.

USAMRIID Focuses on Genome Sequencing to Detect Variants

Article
1/5/2023
Military medical personnel in laboratory

A connected family of laboratories across the MHS allows a more rapid response to the outbreak.

Whole Genome Sequencing at Tripler Army Medical Center

Article
12/29/2022
Dr. Keith Fong reviews data with other lab technicians

The third installment in a 6-part series highlighting the efforts of the Military Health System laboratories and the technicians who worked to identify COVID-19 variants using special sequencing technology.

Walter Reed Army Institute of Research Implements SARS-CoV-2 Genome Sequencing

Article
12/23/2022
Military medical personnel in laboratory

This is the second article in a 6-part series that highlights the work of technicians and scientists in Military Health System laboratories who worked to identify COVID-19 variants using special sequencing technology.

Protect Yourself With Respiratory Illnesses on the Rise

Article Around MHS
12/19/2022
Military medical personnel administering vaccine

"Tis the season, and respiratory illnesses are on the rise. Learn critical health guidance about the viral triple threat of COVID-19, influenza, and the common cold, and the commonsense steps you can take to protect yourself and your family.

Military Labs Use Whole Genome Sequencing of COVID-19 Variants

Article
12/16/2022
Lab technician at work

The first in a 6-part series highlighting the work of technicians and scientists working in support of the MHS who identified COVID-19 variants using special sequencing technology.

DOD Reduces Health Care Waste by Reusing Crutches

Article
12/15/2022
Military personnel using crutches

When military facilities faced a national shortage of an essential mobility aid, they launched a grassroots initiative that not only ensured patient care, but also created a new waste reduction model within the DHA.

MHS Minute | Nov 2022

Video
12/12/2022
MHS Minute | Nov 2022

The latest MHS Minute focuses on highlights from DHA Director Lt. Gen. Ronald J. Place’s final virtual town hall with the workforce, Nov. 16, 2022. The discussion included the agency’s biggest accomplishments over the past three years and the impact of COVID-19 on DHA’s reputation and approach to health care delivery.

Flu Season’s Here: You Still Can Get Your Flu Shot for Protection

Article
12/12/2022
Flu Week Infographic

It’s not too late to get vaccinated against the flu and COVID-19.

Naval Medical Research Center Joint Study with Mount Sinai Uncovers Differences in COVID-19 Immune Response between the Sexes

Article Around MHS
12/5/2022
Amanda Cherry, research assistant, performing diagnostic testing at NMRC

A collaborative study between researchers at Naval Medical Research Center and the Icahn School of Medicine at Mount Sinai, and Princeton University has highlighted immune response differences in the coronavirus infection responses between male and female patients.

Page 1 of 25 , showing items 1 - 15
First < 1 2 3 4 5  ... > Last 
Refine your search
Last Updated: May 04, 2023
Follow us on Instagram Follow us on LinkedIn Follow us on Facebook Follow us on Twitter Follow us on YouTube Sign up on GovDelivery